December 21, 2016

Incyte and Merus Announce Global Strategic Research Collaboration to Discover and Develop Bispecific Antibodies

UTRECHT, The Netherlands, Dec. 21, 2016 (GLOBE NEWSWIRE)

Today, Merus N.V. (NASDAQ:MRUS) and Incyte Corporation (NASDAQ:INCY) announced that they have entered a global strategic research collaboration focused on the research, discovery and development of bispecific antibodies utilizing Merus’ proprietary Biclonics® technology platform. The Collaboration and License Agreement grants Incyte the exclusive rights for up to eleven bispecific antibody research programs, including two of Merus’ current preclinical immuno-oncology discovery programs.

Merus will host a conference call today to discuss this strategic research collaboration at 8:30 a.m. ET, 2:30 p.m. CET. Participants may access the call by dialing 866-978-9968 in the U.S. or 646-722-4972 outside the U.S. and referencing conference ID number 72944512#. The conference call will also be available by webcast on the Investor Relations page of Merus’ website, An audio replay of the call will be available from 11:30 a.m. ET on December 21, 2016 until 11:30 a.m. ET on January 4, 2017. To access the replay from both within and outside the U.S., dial 866-535-8030. The participant passcode is 680343#.

Further information

Eliza Schleifstein, Media
+1 973 361 1546

Kimberly Minarovich, Investors
+1 646 368 8014